These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15565349)

  • 21. [Biphosphonates for the prevention of osteoporosis in postmenopausal women with a low bone mass].
    Pelayo M; Agra Y
    Med Clin (Barc); 2004 Mar; 122(8):304-10. PubMed ID: 15030743
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of postmenopausal osteoporosis in the general medical practice (clinical case)].
    Zhdan VM; Kitura OIe; Kitura IeM; Babanina MIu; Tkachenko MV
    Lik Sprava; 2013 Mar; (2):85-9. PubMed ID: 24605616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
    Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
    J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Osteoporosis].
    Pfeilschifter J
    MMW Fortschr Med; 2004 Mar; 146(11):61, 63. PubMed ID: 15152780
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Osteoporosis-induced fractures. Bisphosphonates lower risk also in the hip].
    MMW Fortschr Med; 2000 Jul; 142(30):52-3. PubMed ID: 10955025
    [No Abstract]   [Full Text] [Related]  

  • 29. [Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate].
    Riancho JA
    Rev Clin Esp; 1999 Jun; 199(6):349-55. PubMed ID: 10432808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alendronate in postmenopausal osteoporosis.
    McGrath H
    N Engl J Med; 1996 Mar; 334(11):734; author reply 734-5. PubMed ID: 8594443
    [No Abstract]   [Full Text] [Related]  

  • 32. An overview of osteoporosis.
    Shepherd AJ
    Altern Ther Health Med; 2004; 10(2):26-33; quiz 34, 92. PubMed ID: 15055091
    [No Abstract]   [Full Text] [Related]  

  • 33. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study shows that a new type of osteoporosis drug reduces fracture risk.
    Harv Womens Health Watch; 2009 Oct; 17(2):6-7. PubMed ID: 19998553
    [No Abstract]   [Full Text] [Related]  

  • 35. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
    Reginster JY; Seeman E; De Vernejoul MC; Adami S; Compston J; Phenekos C; Devogelaer JP; Curiel MD; Sawicki A; Goemaere S; Sorensen OH; Felsenberg D; Meunier PJ
    J Clin Endocrinol Metab; 2005 May; 90(5):2816-22. PubMed ID: 15728210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing osteoporotic fractures with alendronate.
    Maughan KL
    J Fam Pract; 1997 Apr; 44(4):336. PubMed ID: 9148031
    [No Abstract]   [Full Text] [Related]  

  • 39. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
    Jansen JP; Bergman GJ; Huels J; Olson M
    Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.